Similar changes in cognitions following cognitive-behavioral therapy or escitalopram for major depressive disorder

Implications for mechanisms of change

Amy Farabaugh, Lauren Fisher, Maren Nyer, Daphne Holt, Mariana Cohen, Lee Baer, Benjamin G. Shapero, Ilana Huz, Amber Cardoos, Maurizio Fava, Jonathan E. Alpert

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

BACKGROUND: Psychosocial treatments and medications both have been shown to be effective in treating major depressive disorder. We hypothesized that cognitive-behavioral therapy (CBT) would outperform medication on measures of cognitive change. METHODS: We randomized depressed individuals to 12 weeks of CBT (n = 15) or escitalopram (n = 11). In an intent-to-treat analysis (n = 26), we conducted a repeated measures analysis of variance to examine changes in depressive symptoms (ie, 17-item Hamilton Depression Rating Scale, Beck Depression Inventory), anhedonia (ie, Snaith-Hamilton Pleasure Scale), cognitive measures (ie, Dysfunctional Attitudes Scale, Automatic Thoughts Questionnaire, Perceived Stress Scale), and quality of life (ie, Quality of Life Enjoyment and Satisfaction Questionnaire) at 4 time points: baseline, week 4, week 8, and week 12. Treatment for both groups started at baseline, and patients received either 12 weeks of individual CBT or 12 weeks of escitalopram with flexible dosing (10 to 20 mg). RESULTS: Collapsing the escitalopram and CBT groups, there were statistically significant pre-post changes on all outcome measures. However, there were no statistically significant differences between treatment groups on any of the outcome measures, including cognitive measures across time points. CONCLUSIONS: Our results suggest that both CBT and escitalopram have similar effects across a variety of domains and that, in contrast to our a priori hypothesis, CBT and escitalopram were associated with comparable changes on cognitive measures.

Original languageEnglish (US)
Pages (from-to)118-125
Number of pages8
JournalAnnals of Clinical Psychiatry
Volume27
Issue number2
StatePublished - May 1 2015
Externally publishedYes

Fingerprint

Citalopram
Major Depressive Disorder
Cognitive Therapy
Cognition
Quality of Life
Depression
Outcome Assessment (Health Care)
Anhedonia
Pleasure
Analysis of Variance
Therapeutics
Equipment and Supplies

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Medicine(all)

Cite this

Similar changes in cognitions following cognitive-behavioral therapy or escitalopram for major depressive disorder : Implications for mechanisms of change. / Farabaugh, Amy; Fisher, Lauren; Nyer, Maren; Holt, Daphne; Cohen, Mariana; Baer, Lee; Shapero, Benjamin G.; Huz, Ilana; Cardoos, Amber; Fava, Maurizio; Alpert, Jonathan E.

In: Annals of Clinical Psychiatry, Vol. 27, No. 2, 01.05.2015, p. 118-125.

Research output: Contribution to journalArticle

Farabaugh, A, Fisher, L, Nyer, M, Holt, D, Cohen, M, Baer, L, Shapero, BG, Huz, I, Cardoos, A, Fava, M & Alpert, JE 2015, 'Similar changes in cognitions following cognitive-behavioral therapy or escitalopram for major depressive disorder: Implications for mechanisms of change', Annals of Clinical Psychiatry, vol. 27, no. 2, pp. 118-125.
Farabaugh, Amy ; Fisher, Lauren ; Nyer, Maren ; Holt, Daphne ; Cohen, Mariana ; Baer, Lee ; Shapero, Benjamin G. ; Huz, Ilana ; Cardoos, Amber ; Fava, Maurizio ; Alpert, Jonathan E. / Similar changes in cognitions following cognitive-behavioral therapy or escitalopram for major depressive disorder : Implications for mechanisms of change. In: Annals of Clinical Psychiatry. 2015 ; Vol. 27, No. 2. pp. 118-125.
@article{3e57108e37504d15aa6e46ebee0e08ed,
title = "Similar changes in cognitions following cognitive-behavioral therapy or escitalopram for major depressive disorder: Implications for mechanisms of change",
abstract = "BACKGROUND: Psychosocial treatments and medications both have been shown to be effective in treating major depressive disorder. We hypothesized that cognitive-behavioral therapy (CBT) would outperform medication on measures of cognitive change. METHODS: We randomized depressed individuals to 12 weeks of CBT (n = 15) or escitalopram (n = 11). In an intent-to-treat analysis (n = 26), we conducted a repeated measures analysis of variance to examine changes in depressive symptoms (ie, 17-item Hamilton Depression Rating Scale, Beck Depression Inventory), anhedonia (ie, Snaith-Hamilton Pleasure Scale), cognitive measures (ie, Dysfunctional Attitudes Scale, Automatic Thoughts Questionnaire, Perceived Stress Scale), and quality of life (ie, Quality of Life Enjoyment and Satisfaction Questionnaire) at 4 time points: baseline, week 4, week 8, and week 12. Treatment for both groups started at baseline, and patients received either 12 weeks of individual CBT or 12 weeks of escitalopram with flexible dosing (10 to 20 mg). RESULTS: Collapsing the escitalopram and CBT groups, there were statistically significant pre-post changes on all outcome measures. However, there were no statistically significant differences between treatment groups on any of the outcome measures, including cognitive measures across time points. CONCLUSIONS: Our results suggest that both CBT and escitalopram have similar effects across a variety of domains and that, in contrast to our a priori hypothesis, CBT and escitalopram were associated with comparable changes on cognitive measures.",
author = "Amy Farabaugh and Lauren Fisher and Maren Nyer and Daphne Holt and Mariana Cohen and Lee Baer and Shapero, {Benjamin G.} and Ilana Huz and Amber Cardoos and Maurizio Fava and Alpert, {Jonathan E.}",
year = "2015",
month = "5",
day = "1",
language = "English (US)",
volume = "27",
pages = "118--125",
journal = "Annals of Clinical Psychiatry",
issn = "1040-1237",
publisher = "Dowden Health Media,Inc",
number = "2",

}

TY - JOUR

T1 - Similar changes in cognitions following cognitive-behavioral therapy or escitalopram for major depressive disorder

T2 - Implications for mechanisms of change

AU - Farabaugh, Amy

AU - Fisher, Lauren

AU - Nyer, Maren

AU - Holt, Daphne

AU - Cohen, Mariana

AU - Baer, Lee

AU - Shapero, Benjamin G.

AU - Huz, Ilana

AU - Cardoos, Amber

AU - Fava, Maurizio

AU - Alpert, Jonathan E.

PY - 2015/5/1

Y1 - 2015/5/1

N2 - BACKGROUND: Psychosocial treatments and medications both have been shown to be effective in treating major depressive disorder. We hypothesized that cognitive-behavioral therapy (CBT) would outperform medication on measures of cognitive change. METHODS: We randomized depressed individuals to 12 weeks of CBT (n = 15) or escitalopram (n = 11). In an intent-to-treat analysis (n = 26), we conducted a repeated measures analysis of variance to examine changes in depressive symptoms (ie, 17-item Hamilton Depression Rating Scale, Beck Depression Inventory), anhedonia (ie, Snaith-Hamilton Pleasure Scale), cognitive measures (ie, Dysfunctional Attitudes Scale, Automatic Thoughts Questionnaire, Perceived Stress Scale), and quality of life (ie, Quality of Life Enjoyment and Satisfaction Questionnaire) at 4 time points: baseline, week 4, week 8, and week 12. Treatment for both groups started at baseline, and patients received either 12 weeks of individual CBT or 12 weeks of escitalopram with flexible dosing (10 to 20 mg). RESULTS: Collapsing the escitalopram and CBT groups, there were statistically significant pre-post changes on all outcome measures. However, there were no statistically significant differences between treatment groups on any of the outcome measures, including cognitive measures across time points. CONCLUSIONS: Our results suggest that both CBT and escitalopram have similar effects across a variety of domains and that, in contrast to our a priori hypothesis, CBT and escitalopram were associated with comparable changes on cognitive measures.

AB - BACKGROUND: Psychosocial treatments and medications both have been shown to be effective in treating major depressive disorder. We hypothesized that cognitive-behavioral therapy (CBT) would outperform medication on measures of cognitive change. METHODS: We randomized depressed individuals to 12 weeks of CBT (n = 15) or escitalopram (n = 11). In an intent-to-treat analysis (n = 26), we conducted a repeated measures analysis of variance to examine changes in depressive symptoms (ie, 17-item Hamilton Depression Rating Scale, Beck Depression Inventory), anhedonia (ie, Snaith-Hamilton Pleasure Scale), cognitive measures (ie, Dysfunctional Attitudes Scale, Automatic Thoughts Questionnaire, Perceived Stress Scale), and quality of life (ie, Quality of Life Enjoyment and Satisfaction Questionnaire) at 4 time points: baseline, week 4, week 8, and week 12. Treatment for both groups started at baseline, and patients received either 12 weeks of individual CBT or 12 weeks of escitalopram with flexible dosing (10 to 20 mg). RESULTS: Collapsing the escitalopram and CBT groups, there were statistically significant pre-post changes on all outcome measures. However, there were no statistically significant differences between treatment groups on any of the outcome measures, including cognitive measures across time points. CONCLUSIONS: Our results suggest that both CBT and escitalopram have similar effects across a variety of domains and that, in contrast to our a priori hypothesis, CBT and escitalopram were associated with comparable changes on cognitive measures.

UR - http://www.scopus.com/inward/record.url?scp=84955510005&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84955510005&partnerID=8YFLogxK

M3 - Article

VL - 27

SP - 118

EP - 125

JO - Annals of Clinical Psychiatry

JF - Annals of Clinical Psychiatry

SN - 1040-1237

IS - 2

ER -